Mainz Biomed
Mainz Biomed
MYNZ
NASDAQ
4.89
USD
4.94%
About
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis.
The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.6M |
| Three Month Average Volume | 24.3M |
| High Low | |
| Fifty-Two Week High | 4.38 USD |
| Fifty-Two Week Low | 0.306 USD |
| Fifty-Two Week High Date | 13 Sep 2023 |
| Fifty-Two Week Low Date | 16 Aug 2024 |
| Price and Volume | |
| Current Price | 0.3537 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -7.00% |
| Thirteen Week Relative Price Change | -61.98% |
| Twenty-Six Week Relative Price Change | -65.45% |
| Fifty-Two Week Relative Price Change | -90.78% |
| Year-to-Date Relative Price Change | -74.25% |
| Price Change | |
| One Day Price Change | -2.43% |
| Thirteen Week Price Change | -59.31% |
| Twenty-Six Week Price Change | -62.01% |
| Five Day Price Change | -1.48% |
| Fifty-Two Week Price Change | -88.44% |
| Year-to-Date Price Change | -69.51% |
| Month-to-Date Price Change | -24.20% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.15352 USD |
| Book Value Per Share (Most Recent Quarter) | 0.15352 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.00687 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.00687 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.58174 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.05513 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.0554 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.61896 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.66598 USD |
| Normalized (Last Fiscal Year) | -1.62237 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.61896 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.66598 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.61896 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.66598 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.33408 USD |
| Cash Per Share (Most Recent Quarter) | 0.33408 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.565 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.56015 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.47467 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -2,662 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2,936.50% |
| Pretax Margin (Last Fiscal Year) | -2,936.50% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 56.91% |
| Gross Margin (Trailing Twelve Months) | 56.91% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -2,969.29% |
| Operating Margin (Trailing Twelve Months) | -2,969.29% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -2,936.50% |
| Net Profit Margin (Trailing Twelve Months) | -2,936.50% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 21.97% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -99,999.99% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -680,320 |
| Net Debt (Last Fiscal Year) | -680,320 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 9 |
| Price to Sales (Trailing Twelve Months) | 9 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 36 |
| Long Term Debt to Equity (Most Recent Quarter) | 36 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,837,690 |
| Free Cash Flow (Trailing Twelve Months) | -23,837,690 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -33 |
| Net Interest Coverage (Trailing Twelve Months) | -33 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 197 |
| Total Debt to Equity (Most Recent Quarter) | 197 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -147.52% |
| Return on Assets (Trailing Twelve Months) | -147.52% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -303.20% |
| Return on Equity (Trailing Twelve Months) | -303.20% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -237.21% |
| Return on Investment (Trailing Twelve Months) | -237.21% |
| Return on Investment (5 Year) | -99,999.99% |